Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had its target price raised by research analysts at Credit Suisse Group from $5.65 to $81.00 in a report released on Thursday. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Credit Suisse Group’s price target would suggest a potential upside of 88.33% from the stock’s current price.

Several other equities analysts also recently commented on the company. Barclays PLC assumed coverage on Sarepta Therapeutics in a report on Wednesday. They set an “equal weight” rating and a $46.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday. Robert W. Baird reiterated an “outperform” rating and set a $101.00 price target on shares of Sarepta Therapeutics in a report on Wednesday. Nomura reiterated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Finally, BidaskClub downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $62.31.

Sarepta Therapeutics (SRPT) opened at 43.01 on Thursday. The stock’s 50 day moving average is $39.34 and its 200-day moving average is $34.16. The firm’s market capitalization is $2.77 billion. Sarepta Therapeutics has a 52-week low of $25.47 and a 52-week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. During the same quarter last year, the business earned ($1.19) EPS. The company’s revenue for the quarter was up 350000.0% on a year-over-year basis. Equities analysts expect that Sarepta Therapeutics will post ($1.23) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Price Target Raised to $81.00 at Credit Suisse Group” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/10/sarepta-therapeutics-inc-srpt-price-target-raised-to-81-00-at-credit-suisse-group.html.

In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the transaction, the senior vice president now directly owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sandesh Mahatme sold 50,000 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $2,050,000.00. Following the transaction, the chief financial officer now owns 41,736 shares of the company’s stock, valued at $1,711,176. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 over the last quarter. Corporate insiders own 9.60% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its stake in Sarepta Therapeutics by 4,403.1% during the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after acquiring an additional 5,175,193 shares in the last quarter. Vanguard Group Inc. raised its stake in Sarepta Therapeutics by 4.0% during the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after acquiring an additional 162,543 shares in the last quarter. State Street Corp raised its stake in Sarepta Therapeutics by 21.2% during the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after acquiring an additional 559,342 shares in the last quarter. HealthCor Management L.P. raised its stake in Sarepta Therapeutics by 31.1% during the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares in the last quarter. Finally, Camber Capital Management LLC acquired a new position in Sarepta Therapeutics during the first quarter worth $39,960,000. Hedge funds and other institutional investors own 65.43% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.